サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1498536

放射性医薬品の市場規模および予測、世界および地域シェア、動向、成長機会分析レポート：用途別、タイプ別、トレーサータイプ別、エンドユーザー別、地域別

Radiopharmaceuticals Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, Type, Tracer Type, End User, and Geography

出版日
ページ情報
英文 237 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.37円
放射性医薬品の市場規模および予測、世界および地域シェア、動向、成長機会分析レポート：用途別、タイプ別、トレーサータイプ別、エンドユーザー別、地域別
出版日: 2024年05月23日
発行: The Insight Partners
ページ情報: 英文 237 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

放射性医薬品の市場規模は、2023年の90億7,000万米ドルから2031年には265億1,000万米ドルに急増すると予測されており、2023～2031年のCAGRは14.4%を記録すると予測されています。慢性疾患の有病率の上昇と標的治療における臨床試験の増加が放射性医薬品市場の成長を後押ししています。

放射性医薬品は、加齢関連疾患の診断と治療を効率的に処理できることが証明されています。改良されたターゲティング能力、より長い半減期、より少ない副作用を持つ放射性医薬品の開発により、様々な用途でより魅力的なものとなっています。単一の放射性医薬品に診断機能と治療機能を併せ持つセラノスティクスの調査は有望であり、市場成長をさらに促進する可能性があります。世界各国の政府が健康状態の改善における放射性医薬品の価値を認識しているため、新しい放射性医薬品の研究開発に対する資金提供の増加や、放射性医薬品の承認に向けた規制当局の支援が観察されています。さらに、市場は変化するヘルスケアの需要に対応するために進歩しており、高度な診断技術を用いた放射性医薬品施設の進化が、今後数年間に新たな放射性医薬品市場動向をもたらすと予想されます。

慢性疾患の増加が放射性医薬品市場を牽引

肺疾患、がん、脳卒中、アルツハイマー病、心血管疾患（CVD）、慢性腎臓病、各種神経疾患などの慢性疾患は、世界中で急速に増加しています。世界保健機関（WHO）によると、2020年には世界全体でがんによる死亡が1,000万人に達すると報告されています。同様に、米国がん協会の推計によると、2020年には米国で新たに180万6590人のがん患者が診断されます。全国がん登録プログラム報告書2020によると、インドでは、男性で679,421人のがん症例が報告され、その数は2025年までに～763,575人に増加すると予測されています。一方、女性では、2020年に712,758人のがん症例が記録され、その数は2025年までに806,218人に達すると予測されています。米国がん協会の報告書によると、2023年には43,720人（女性31,180人、男性12,540人）の甲状腺がん患者が新たに発生します。CVDは、高い死亡率をもたらす慢性疾患の中で最も蔓延している種類の一つです。米国疾病予防管理センターは、心臓病が米国における死因の第1位であるとしています。同出典によると、2020年には、米国では～697,000人、i.5人に1人が心臓病が原因で死亡しています。パーキンソン財団によると、パーキンソン症状は通常60歳以上で見られます。カナダ心理学会によると、カナダでは人口の約2％が強迫性障害に苦しんでいます。WHOによると、神経疾患は世界の疾病負担の6.3％を占めており、世界の主要死因の1つでもあります。先進国および中低所得国では、それぞれ13.2%と16.8%が神経疾患による死亡であると報告されています。放射性医薬品は、神経疾患や神経変性疾患、筋骨格系疾患の診断において高い有効性が実証されています。放射性医薬品は、その二重の機能性により他とは一線を画しています。放射性医薬品は、疾患の可視性を高めるだけでなく、重要な機能的情報を提供します。様々な方法がある中で、放射性同位元素による細胞標識は、細胞を追跡してその生体内分布を調べるための最も有望な技術の一つです。このように、慢性疾患の急増が放射性医薬品市場の成長を牽引しています。

市場動向

進化する放射性医薬品施設

核医学は多くの変化を遂げている分野です。放射性医薬品の急速な進化に伴い、PETや放射線治療薬などのより高度な診断技術が広く使用されるようになっています。低所得国では、国際原子力機関（IAEA）の努力により、この技術はまだ確立されていないが、米国のような技術先進国では、特にセラノスティクスの出現により、標準治療へと進化しつつあります。

アフリカのいくつかの国では、IAEAの技術協力プログラムや調整された研究プロジェクトの支援を受けて、放射性医薬品を製造するための放射性医薬品施設の拡大と近代化に取り組んでいます。例えば、北アフリカのチュニジアでは、IAEAの支援を受けてPETの使用を開始しました。同時にアルジェリアでは、医療用サイクロトロンが設置され、稼働を開始しました。この装置により、同国は放射性医薬品を製造できるようになり、リンパ腫や肺がん、大腸がんなど、多くの種類のがんに対するPETによる定期的な画像診断が可能になった。

放射性医薬品の動向に関する国際シンポジウムでは、放射性医薬品化学と核医学の明るい未来が紹介されます。アイソトープ製造、放射化学の進歩、新規放射性医薬品のヒト試験への応用は、エキサイティングな結果をもたらします。特に、イメージングを利用して標的治療を誘導するセラノスティック戦略や、成長する研究分野は、世界の核医学界が新しい放射線治療薬の開発を通じて個別化医療の可能性を実現するのに役立っています。セラノスティックスは、診断と治療を単一のアプローチで融合させるものです。放射性トレーサーは特定の標的を同定し（診断）、次に標的治療を行う。このアプローチにより、医師は治療に対する反応をリアルタイムで評価することで、患者の治療計画を個別化することができます。セラノスティックスは、前立腺がんや神経内分泌腫瘍など、特定のがんの治療に特に有望です。新しい放射性トレーサーやイメージング薬剤により、分子イメージングがより特異的で高感度なものとなり、より早期かつ正確な疾患検出が可能となっています。さらに、PET-CTやPET-MRIのようなハイブリッドイメージングは、2つ以上の画像モダリティを組み合わせて、補完的な情報を提供し、診断精度を向上させる。これらのアプローチは、機能的情報と解剖学的情報を組み合わせることで、疾患プロセスの包括的な概観を可能にします。したがって、このような発展とアプローチは、今後の市場成長を牽引するものと期待されます。

放射性医薬品の世界市場」は、用途、トレーサータイプ、エンドユーザー、地域によって区分されます。

用途ベースの洞察

放射性医薬品市場は、腫瘍学、循環器学、神経学、呼吸器学、泌尿器学、その他の各分野に分類されます。がん分野は2023年に最大の市場シェアを占め、予測期間中に14.8%の最高CAGRを記録すると予測されています。がんは、死亡率の高い主要な健康問題の1つです。WHOの発表によると、2020年には世界で新たに1,010万人のがん患者が診断され、1,000万人ががんで死亡したと推定されています。がん患者の診断と治療には、正確な管理決定と最適な転帰を保証するための画像診断へのアクセスが必要です。がんの治療には核医学療法が用いられ、最も一般的な放射性トレーサーはF-18フルオロデオキシグルコース（FDG）です。FDGはブドウ糖に似ており、がん細胞は代謝が活発であるため、ブドウ糖の吸収率が高くなります。これがPET検査で確認できるため、ヘルスケア専門家は病気を発見することができます。フルオロデオキシグルコースとして標識されたフッ素-i8は、悪性腫瘍と良性腫瘍を区別し、病気の程度を判定するのに効果的です。2018年1月にFDAがルテチウムLu 177ドタテート（Lutathera）を承認したことで、神経内分泌腫瘍（NET）の患者はPRRTへのアクセスが広がった。

エンドユーザーに基づく洞察

エンドユーザー別では、市場は病院・診療所、診断センター、学術・研究機関、その他に区分されます。病院・診療所セグメントは、2023年の放射性医薬品市場シェアを独占しました。診断センターセグメントは、2023-2031年に14.8%の最高CAGRを記録すると予測されています。病院や診療所では、心臓動脈瘤、腫瘍、神経動脈瘤、その他の治療処置に技術的に進んだ治療を利用しています。心血管系や神経系の動脈瘤治療に対するニーズの高まりは、病院・診療所セグメントの市場成長を促進する主な要因の1つとなっています。継続的な患者のケアとモニタリングのため、手術のほとんどは病院で行われています。

米国食品医薬品局、欧州連合、世界保健機関（WHO）、国際原子力機関（IAEA）、米国疾病管理予防センター（Centers For Disease Control And Prevention）、国立がん研究所（National Cancer Institute）、米国医薬品庁（National Medical Products Administration）、経済協力開発機構（Organization for Economic Co-Operation And Development）、カナダ原子力安全委員会（Canadian Nuclear Safety Commission）などは、放射性医薬品市場調査報告書を作成する際に参照した関連情報源の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 放射性医薬品市場情勢

  • PEST分析
  • 価格分析
    • 地域別価格分析、米国（1回投与あたり）

第5章 放射性医薬品市場- 主な市場力学

  • 放射性医薬品市場- 主な市場力学
  • 市場促進要因
    • 慢性疾患の有病率の上昇
    • 標的治療における臨床試験数の増加
  • 市場抑制要因
    • 放射性医薬品の短い賞味期限
  • 市場機会
    • 新興諸国における高い成長の可能性
  • 今後の動向
    • 進化する放射性医薬品施設
  • 促進要因と抑制要因の影響

第6章 放射性医薬品市場：世界市場分析

  • 放射性医薬品市場の収益、2023-2031年

第7章 放射性医薬品市場の分析：用途別

  • 腫瘍学
  • 循環器
  • 神経学
  • 呼吸器
  • 泌尿器科
  • その他

第8章 放射性医薬品市場の分析：タイプ別

  • 診断
  • 治療

第9章 放射性医薬品市場の分析：トレーサータイプ別

  • Tc-99m
  • F-18
  • Ga-68
  • TL-201
  • I-131
  • Fe-59
  • Lu-171
  • RB-82とN-13
  • Cr-51とP-32
  • Sc-46
  • Sg-269とHs-269
  • その他

第10章 放射性医薬品市場の分析：エンドユーザー別

  • 病院および診療所
  • 診断センター
  • 学術・研究機関
  • その他

第11章 放射性医薬品市場：地域別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • APACのその他諸国
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東とアフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第12章 放射性医薬品市場：業界情勢

  • 放射性医薬品市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第13章 企業プロファイル

  • Cardinal Health Inc
  • Curium
  • General Electric Co
  • Medi-Radiopharma
  • Rotem Industries Ltd
  • ABX advanced biochemical compounds GmbH
  • Invicro LLC
  • Newcastle University
  • Novartis AG
  • Blue Earth Diagnostics Limited
  • IBA Radiopharma Solutions

第14章 付録

図表

List Of Tables

  • Table 1. Radiopharmaceuticals Market Segmentation
  • Table 2. Regional Pricing Analysis, US$ (Per Dose), 2023
  • Table 3. Ongoing Targeted Alpha Therapy Clinical Trials
  • Table 4. Physical Half-Lives of Some Medical Radionuclides for Diagnostic and Therapeutic Use
  • Table 5. Some Other Radionuclides Used in Diagnostic Radiopharmaceuticals
  • Table 6. Some Other Radionuclides Used in Therapeutic Radiopharmaceuticals
  • Table 7. Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Diagnostic
  • Table 8. Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Therapeutic
  • Table 9. Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Tc-99m
  • Table 10. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 11. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 12. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 13. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 14. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 15. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 16. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 17. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 18. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 19. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 20. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 21. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 22. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 23. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 24. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 25. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 26. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 27. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 28. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 29. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 30. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 31. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 32. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 33. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 34. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 35. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 36. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 37. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 38. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 39. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 40. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 41. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 42. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 43. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 44. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 45. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 46. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 47. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 48. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 49. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 50. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 51. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 52. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 53. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 54. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 55. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 56. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 57. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 58. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 59. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 60. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 61. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 62. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 63. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 64. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 65. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 66. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 67. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 68. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 69. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 70. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 71. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 72. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 73. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 74. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 75. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 76. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 77. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 78. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 79. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 80. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 81. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 82. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 83. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 84. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 85. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 86. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 87. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 88. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 89. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 90. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 91. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 92. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 93. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 94. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 95. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 96. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 97. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 98. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 99. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 100. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 101. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 102. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 103. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 104. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 105. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 106. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 107. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 108. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 109. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 110. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 111. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 112. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 113. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 114. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 115. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 116. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 117. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 118. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 119. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 120. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 121. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 122. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 123. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 124. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 125. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 126. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 127. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 128. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 129. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 130. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 131. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 132. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 133. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 134. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 135. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 136. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 137. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 138. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 139. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 140. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 141. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 142. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 143. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 144. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 145. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 146. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 147. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 148. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 149. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 150. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 151. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 152. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 153. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 154. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 155. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 156. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 157. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 158. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 159. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 160. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 161. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 162. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 163. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 164. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 165. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 166. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 167. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 168. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 169. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 170. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 171. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 172. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 173. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 174. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 175. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 176. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 177. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 178. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 179. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 180. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 181. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 182. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 183. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 184. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 185. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 186. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 187. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 188. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 189. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 190. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 191. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 192. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 193. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Type
  • Table 194. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Diagnostic
  • Table 195. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Therapeutic
  • Table 196. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tracer Type
  • Table 197. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by Tc-99m
  • Table 198. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - by End User
  • Table 199. Recent Inorganic Growth Strategies in the Radiopharmaceuticals Market
  • Table 200. Recent Organic Growth Strategies in the Radiopharmaceuticals Market
  • Table 201. Glossary of Terms, Radiopharmaceuticals Market

List Of Figures

  • Figure 1. Radiopharmaceuticals Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Radiopharmaceuticals Market Revenue (US$ Million), 2023-2031
  • Figure 5. Bioprocessing Market Breakdown by Geography, 2023 and 2031 (%)
  • Figure 6. Radiopharmaceuticals Market Share (%) - by Application (2023 and 2031)
  • Figure 7. Oncology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Cardiology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Neurology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Pulmonary: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Urology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Radiopharmaceuticals Market Share (%) - by Type (2023 and 2031)
  • Figure 14. Diagnostic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Therapeutic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Radiopharmaceuticals Market Share (%) - by Tracer Type (2023 and 2031)
  • Figure 17. Tc-99m: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. F-18: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Ga-68: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. TL-201: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. I-131: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Fe-59: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Lu-171: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. RB-82 and N-13: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Cr-51 and P-32: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Sc-46: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Sg-269 and Hs-269: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 29. Radiopharmaceuticals Market Share (%) - by End User (2023 and 2031)
  • Figure 30. Hospitals and Clinics: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. Diagnostic Centers: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. Academic and Research Institutes: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. Radiopharmaceuticals Market Breakdown by Region, 2023 and 2031 (%)
  • Figure 35. North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 36. North America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 37. United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 38. Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 39. Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 40. Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 41. Europe: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 42. Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 43. United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 44. France: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 45. Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 46. Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 47. Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 48. Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 49. Asia Pacific: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 50. China: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 51. Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 52. India: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 53. Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 54. South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 55. Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 56. Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 57. Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 58. Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 59. South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 60. United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 61. Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 62. South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 63. South and Central America: Radiopharmaceuticals Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 64. Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 65. Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 66. Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 67. Growth Strategies in the Radiopharmaceuticals Market
目次
Product Code: TIPRE00003751

The radiopharmaceuticals market size is projected to surge from US$ 9.07 billion in 2023 to US$ 26.51 billion by 2031; the market is estimated to record a CAGR of 14.4% during 2023-2031. The rising prevalence of chronic diseases and the growing number of clinical trials in targeted therapy propel the radiopharmaceuticals market growth.

Radiopharmaceuticals have proven to handle the diagnosis and treatment of age-related diseases efficiently. The development of radiopharmaceuticals with improved targeting capabilities, longer half-lives, and fewer side effects makes them more attractive for various applications. Research into theranostics that combine diagnostic and therapeutic functions in a single radiopharmaceutical is promising and could further drive the market growth. As governments across the world recognize the value of radiopharmaceuticals in improving health outcomes, an increase in the funding for research and development of new radiopharmaceuticals and supportive regulatory pathways for their approval has been observed. Further, the market is progressing toward meeting the demands of a changing healthcare landscape, and the evolving radiopharmacy facilities using advanced diagnostic techniques are expected to bring new radiopharmaceuticals market trends in the coming years.

Rising Prevalence of Chronic Diseases Drives the Radiopharmaceuticals Market

Chronic diseases such as lung diseases, cancer, stroke, Alzheimer's, cardiovascular diseases (CVDs), chronic kidney disease, and various neurological disorders are increasing swiftly across the world. As per the World Health Organization (WHO), in 2020, ~10 million deaths were reported due to cancer globally. Likewise, as per the estimations of the American Cancer Society, in 2020, ~1,806,590 new cases of cancer were diagnosed in the US. As per the National Cancer Registry Program Report 2020, in India, 679,421 cancer cases were reported in males, and the number is anticipated to increase to ~763,575 by 2025; whereas in females, 712,758 cancer cases were recorded in 2020, and the number is predicted to reach 806,218 by 2025. According to the American Cancer Society's report, in 2023, ~43,720 new cases of thyroid cancer (31,180 in women and 12,540 in men) were recorded. CVDs are among the most prevalent types of chronic diseases that result in a high mortality rate. The Centers for Disease Control and Prevention states that heart disease is the leading cause of death in the US. According to the same source, in 2020, ~697,000 deaths, i.e., 1 in 5 deaths, were caused by heart disease in the US. According to the Parkinson's Foundation, Parkinson's symptoms are usually observed in individuals aged 60 years and above. The Canadian Psychological Association states that about 2% of the population in Canada suffers from obsessive-compulsive disorder. As per the WHO, neurological diseases contribute to 6.3% of the global disease burden and are also among the leading causes of death worldwide. 13.2% and 16.8% of deaths are reported due to neurological diseases in developed and low- and middle-income countries, respectively. Radiopharmaceuticals have been demonstrated to have high efficiency in diagnosing neurological and neurodegenerative disorders and musculoskeletal conditions. Radiopharmaceuticals are set apart due to their dual functionality. They not only enhance the visualization of diseases but also provide crucial functional information. Among the various methods available, radioisotope cell labeling is one of the most promising techniques to track cells to investigate their biodistribution. Thus, the surging incidence of chronic diseases is driving the radiopharmaceuticals market growth.

Market Trend

Evolving Radiopharmacy Facilities

Nuclear medicine is a field that is undergoing many changes. As radiopharmaceuticals evolve rapidly, more advanced diagnostic techniques such as PET and radiotherapeutics are becoming more widely used. In low-income countries, the technology is still being established, owing to the efforts by the International Atomic Energy Agency (IAEA), while in some of the technologically advanced countries such as the US, it is evolving into standard care, particularly with the advent of theranostics.

Several African countries are working toward expanding and modernizing their radiopharmaceutical facilities to produce radiopharmaceutical medicines with the help of IAEA's Technical Cooperation Program and coordinated research projects. For instance, with IAEA's support, Tunisia, a country in North Africa, started using PET. At the same time, in Algeria, a medical cyclotron was installed and commissioned. The machine enables the country to produce its radiopharmaceuticals and enables routine PET imaging for many types of cancer, such as lymphoma and lung and colon cancer.

The International Symposium on Trends in Radiopharmaceuticals showcases the bright future of radiopharmaceutical chemistry and nuclear medicine. Advances in isotope production, radiochemistry, and the implementation of novel radiopharmaceuticals in human studies lead to exciting results. In particular, theranostic strategies, which use imaging to guide targeted therapy, and the growing areas of research are helping the global nuclear medicine community realize the potential of personalized medicine through the development of new radiotherapeutics. Theranostics merges diagnostics and therapy in a single approach. Radioactive tracers identify specific targets (diagnosis) and then perform targeted therapies. This approach lets physicians personalize treatment plans for patients by assessing their response to therapy in real time. Theranostics are particularly promising for the treatment of certain forms of cancer, such as prostate cancer and neuroendocrine tumors. With new radiotracers and imaging agents, molecular imaging is becoming more specific and sensitive, enabling earlier and more accurate disease detection. In addition, hybrid imaging, such as PET-CT and PET-MRI, combines two or more imaging modalities to provide complementary information and improve diagnostic accuracy. These approaches combine functional and anatomical information, enabling a comprehensive overview of disease processes. Therefore, such developments and approaches are expected to drive the market growth in the future.

The "Global Radiopharmaceuticals Market" is segmented on the basis of application, tracer type, end user, and geography.

Application-Based Insights

Based on application, the radiopharmaceuticals market analysis is carried out by considering the following segments: oncology, cardiology, neurology, pulmonary, urology, and others. The oncology segment held the largest market share in 2023 and is anticipated to register the highest CAGR of 14.8% during the forecast period. Cancer is one of the major health problems with a high mortality rate. As per the WHO, in 2020, an estimated 10.1 million new cancer cases were diagnosed, and 10 million people died from cancer worldwide. The diagnosis and treatment of patients with cancer require access to imaging to ensure accurate management decisions and optimal outcomes. Nuclear medicine therapy is used to treat cancer, and the most common radiotracer is F-18 fluorodeoxyglucose (FDG). FDG is similar to glucose, and cancer cells are more metabolically active; therefore, they absorb glucose at a higher rate. This can be seen on PET scans and thereby allows the healthcare professional to detect the disease. Fluorine-i8 labeled as flurodeoxyglucose is effective in differentiating malignant from benign tumors and in determining the extent of the disease. People with neuroendocrine tumors (NETs) have wider access to PRRT following the FDA approval of lutetium Lu 177 dotatate (Lutathera) in January 2018.

End User-Based Insights

By end user, the market is segmented into hospitals and clinics, diagnostic centers, academic and research institutes, and others. The hospitals and clinics segment dominated the radiopharmaceuticals market share in 2023. The diagnostic centers segment is anticipated to register the highest CAGR of 14.8% during 2023-2031. Hospitals and clinics utilize technologically advanced treatment for cardiac aneurysms, oncology tumors, neurology aneurysms, and other treatment procedures. The growing need for cardiovascular and neurology aneurysm treatments has become one of the major factors driving the market growth for the hospitals and clinics segment. Most of the surgeries are being performed in hospitals, owing to the continuous patient care and monitoring.

US Food and Drug Administration, European Union, World Health Organization, International Atomic Energy Agency, Centers For Disease Control And Prevention, National Cancer Institute, National Medical Products Administration, Organization For Economic Co-Operation And Development, and Canadian Nuclear Safety Commission are some of the relevant sources referred while preparing the radiopharmaceuticals market research report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Radiopharmaceuticals Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Pricing Analysis
    • 4.3.1 Regional Pricing Analysis, US$ (Per Dose)

5. Radiopharmaceuticals Market - Key Market Dynamics

  • 5.1 Radiopharmaceuticals Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Diseases
    • 5.2.2 Growing Number of Clinical Trials in Targeted Therapy
  • 5.3 Market Restraints
    • 5.3.1 Short Shelf-Life of Radiopharmaceuticals
  • 5.4 Market Opportunities
    • 5.4.1 High Growth Potential in Developing Countries
  • 5.5 Future Trends
    • 5.5.1 Evolving Radiopharmacy Facilities
  • 5.6 Impact of Drivers and Restraints:

6. Radiopharmaceuticals Market - Global Market Analysis

  • 6.1 Radiopharmaceuticals Market Revenue (US$ Million), 2023-2031

7. Radiopharmaceuticals Market Analysis - by Application

  • 7.1 Overview
  • 7.2 Oncology
    • 7.2.1 Overview
    • 7.2.2 Oncology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Cardiology
    • 7.3.1 Overview
    • 7.3.2 Cardiology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Neurology
    • 7.4.1 Overview
    • 7.4.2 Neurology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Pulmonary
    • 7.5.1 Overview
    • 7.5.2 Pulmonary: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Urology
    • 7.6.1 Overview
    • 7.6.2 Urology: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

8. Radiopharmaceuticals Market Analysis - by Type

  • 8.1 Overview
  • 8.2 Diagnostic
    • 8.2.1 Overview
    • 8.2.2 Diagnostic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.2.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Diagnostic
  • 8.3 Therapeutic
    • 8.3.1 Overview
    • 8.3.2 Therapeutic: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 8.3.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Therapeutic

9. Radiopharmaceuticals Market Analysis - by Tracer Type

  • 9.1 Overview
  • 9.2 Tc-99m
    • 9.2.1 Overview
    • 9.2.2 Tc-99m: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.2.2.1 Radiopharmaceuticals Market - Revenue and Forecast to 2031(US$ Million) - By Tc-99m
  • 9.3 F-18
    • 9.3.1 Overview
    • 9.3.2 F-18: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Ga-68
    • 9.4.1 Overview
    • 9.4.2 Ga-68: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.5 TL-201
    • 9.5.1 Overview
    • 9.5.2 TL-201: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.6 I-131
    • 9.6.1 Overview
    • 9.6.2 I-131: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.7 Fe-59
    • 9.7.1 Overview
    • 9.7.2 Fe-59: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.8 Lu-171
    • 9.8.1 Overview
    • 9.8.2 Lu-171: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.9 RB-82 and N-13
    • 9.9.1 Overview
    • 9.9.2 RB-82 and N-13: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.10 Cr-51 and P-32
    • 9.10.1 Overview
    • 9.10.2 Cr-51 and P-32: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.11 Sc-46
    • 9.11.1 Overview
    • 9.11.2 Sc-46: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.12 Sg-269 and Hs-269
    • 9.12.1 Overview
    • 9.12.2 Sg-269 and Hs-269: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.13 Others
    • 9.13.1 Overview
    • 9.13.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

10. Radiopharmaceuticals Market Analysis - by End User

  • 10.1 Overview
  • 10.2 Hospitals and Clinics
    • 10.2.1 Overview
    • 10.2.2 Hospitals and Clinics: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Diagnostic Centers
    • 10.3.1 Overview
    • 10.3.2 Diagnostic Centers: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Academic and Research Institutes
    • 10.4.1 Overview
    • 10.4.2 Academic and Research Institutes: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)

11. Radiopharmaceuticals Market - Geographical Analysis

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 North America Radiopharmaceuticals Market Overview
    • 11.2.2 North America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.3 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
    • 11.2.4 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
      • 11.2.4.1 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
      • 11.2.4.2 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
    • 11.2.5 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
      • 11.2.5.1 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
    • 11.2.6 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.2.7 North America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.2.7.1 United States: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.1.1 United States: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.1.2 United States: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.1.2.1 United States: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.1.2.2 United States: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.1.3 United States: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.1.3.1 United States: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.1.4 United States: Radiopharmaceuticals Market Breakdown, by End User
      • 11.2.7.2 Canada: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.2.2.1 Canada: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.2.2.2 Canada: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.2.3 Canada: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.2.3.1 Canada: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.2.4 Canada: Radiopharmaceuticals Market Breakdown, by End User
      • 11.2.7.3 Mexico: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.2.7.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Application
        • 11.2.7.3.2 Mexico: Radiopharmaceuticals Market Breakdown, by Type
        • 11.2.7.3.2.1 Mexico: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.2.7.3.2.2 Mexico: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.2.7.3.3 Mexico: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.2.7.3.3.1 Mexico: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.2.7.3.4 Mexico: Radiopharmaceuticals Market Breakdown, by End User
  • 11.3 Europe
    • 11.3.1 Europe Radiopharmaceuticals Market Overview
    • 11.3.2 Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.3 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
    • 11.3.4 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
      • 11.3.4.1 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
      • 11.3.4.2 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
    • 11.3.5 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
      • 11.3.5.1 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
    • 11.3.6 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.3.7 Europe: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.3.7.1 Germany: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.1.1 Germany: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.1.2 Germany: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.1.2.1 Germany: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.1.2.2 Germany: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.1.3 Germany: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.1.3.1 Germany: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.1.4 Germany: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.2 United Kingdom: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.2.2.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.2.2.2 United Kingdom: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.2.3 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.2.3.1 United Kingdom: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.2.4 United Kingdom: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.3 France: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.3.1 France: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.3.2 France: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.3.2.1 France: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.3.2.2 France: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.3.3 France: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.3.3.1 France: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.3.4 France: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.4 Italy: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.4.1 Italy: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.4.2 Italy: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.4.2.1 Italy: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.4.2.2 Italy: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.4.3 Italy: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.4.3.1 Italy: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.4.4 Italy: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.5 Spain: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.5.1 Spain: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.5.2 Spain: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.5.2.1 Spain: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.5.2.2 Spain: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.5.3 Spain: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.5.3.1 Spain: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.5.4 Spain: Radiopharmaceuticals Market Breakdown, by End User
      • 11.3.7.6 Rest of Europe: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.3.7.6.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Application
        • 11.3.7.6.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Type
        • 11.3.7.6.2.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.3.7.6.2.2 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.3.7.6.3 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.3.7.6.3.1 Rest of Europe: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.3.7.6.4 Rest of Europe: Radiopharmaceuticals Market Breakdown, by End User
  • 11.4 Asia Pacific
    • 11.4.1 Asia Pacific Radiopharmaceuticals Market Overview
    • 11.4.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.2.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.4.2.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.4.2.2.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.4.2.2.2 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.4.2.3 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.4.2.3.1 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.4.2.4 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.4.3 Asia Pacific: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.4.3.1 China: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.1.1 China: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.1.2 China: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.1.2.1 China: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.1.2.2 China: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.1.3 China: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.1.3.1 China: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.1.4 China: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.2 Japan: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.2.2.1 Japan: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.2.2.2 Japan: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.2.3 Japan: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.2.3.1 Japan: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.2.4 Japan: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.3 India: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.3.2 India: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.3.2.1 India: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.3.2.2 India: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.3.3 India: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.3.3.1 India: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.3.4 India: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.4 Australia: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.4.1 Australia: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.4.2 Australia: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.4.2.1 Australia: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.4.2.2 Australia: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.4.3 Australia: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.4.3.1 Australia: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.4.4 Australia: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.5 South Korea: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.5.1 South Korea: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.5.2 South Korea: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.5.2.1 South Korea: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.5.2.2 South Korea: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.5.3 South Korea: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.5.3.1 South Korea: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.5.4 South Korea: Radiopharmaceuticals Market Breakdown, by End User
      • 11.4.3.6 Rest of APAC: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.4.3.6.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Application
        • 11.4.3.6.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Type
        • 11.4.3.6.2.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.4.3.6.2.2 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.4.3.6.3 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.4.3.6.3.1 Rest of APAC: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.4.3.6.4 Rest of APAC: Radiopharmaceuticals Market Breakdown, by End User
  • 11.5 Middle East and Africa
    • 11.5.1 Middle East and Africa Radiopharmaceuticals Market Overview
    • 11.5.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.2.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.5.2.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.5.2.2.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.5.2.2.2 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.5.2.3 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.5.2.3.1 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.5.2.4 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.5.3 Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.5.3.1 Saudi Arabia: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.1.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.1.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.1.2.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.1.2.2 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.1.3 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.1.3.1 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.1.4 Saudi Arabia: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.2 South Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.2.2.1 South Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.2.2.2 South Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.2.3 South Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.2.3.1 South Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.2.4 South Africa: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.3 United Arab Emirates: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.3.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.3.2.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.3.2.2 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.3.3 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.3.3.1 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.3.4 United Arab Emirates: Radiopharmaceuticals Market Breakdown, by End User
      • 11.5.3.4 Rest of Middle East and Africa: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.5.3.4.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Application
        • 11.5.3.4.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Type
        • 11.5.3.4.2.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.5.3.4.2.2 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.5.3.4.3 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.5.3.4.3.1 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.5.3.4.4 Rest of Middle East and Africa: Radiopharmaceuticals Market Breakdown, by End User
  • 11.6 South and Central America
    • 11.6.1 South and Central America Radiopharmaceuticals Market Overview
    • 11.6.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.6.2.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Application
      • 11.6.2.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Type
        • 11.6.2.2.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Diagnostic
        • 11.6.2.2.2 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Therapeutic
      • 11.6.2.3 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tracer Type
        • 11.6.2.3.1 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Tc-99m
      • 11.6.2.4 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by End User
    • 11.6.3 South and Central America: Radiopharmaceuticals Market - Revenue and Forecast Analysis - by Country
      • 11.6.3.1 Brazil: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.1.1 Brazil: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.1.2 Brazil: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.1.2.1 Brazil: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.1.2.2 Brazil: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.1.3 Brazil: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.1.3.1 Brazil: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.1.4 Brazil: Radiopharmaceuticals Market Breakdown, by End User
      • 11.6.3.2 Argentina: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.2.2.1 Argentina: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.2.2.2 Argentina: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.2.3 Argentina: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.2.3.1 Argentina: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.2.4 Argentina: Radiopharmaceuticals Market Breakdown, by End User
      • 11.6.3.3 Rest of South and Central America: Radiopharmaceuticals Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.6.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Application
        • 11.6.3.3.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Type
        • 11.6.3.3.2.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Diagnostic
        • 11.6.3.3.2.2 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Therapeutic
        • 11.6.3.3.3 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tracer Type
        • 11.6.3.3.3.1 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by Tc-99m
        • 11.6.3.3.4 Rest of South and Central America: Radiopharmaceuticals Market Breakdown, by End User

12. Radiopharmaceuticals Market-Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Radiopharmaceuticals Market
  • 12.3 Inorganic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Organic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Cardinal Health Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Curium
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 General Electric Co
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Medi-Radiopharma
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Rotem Industries Ltd
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 ABX advanced biochemical compounds GmbH
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Invicro LLC
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Newcastle University
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Novartis AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Blue Earth Diagnostics Limited
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 IBA Radiopharma Solutions
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms